Alzheimer's

Research of a new medical food

Alzheimer's

Bioiberica is investigating a new compound of animal origin, isolated from the porcine brain and completely developed by the company, that has already achieved positive results in slowing down the progression of Alzheimer's in seven studies using animals. This compound is PRJ212, which has a new mechanism of action based on neuroprotection and which could prevent memory loss in patients at the mild stage. The company is planning to begin clinical trials in Alzheimer patients in the last quarter of this year 2015.

Bioiberica's goal is to launch a medical food onto the market, a food used for medical prurposes which, consumed regurlarly, helps prevent memory loss in patients with mild Alzheimer's. 

Bioiberica is a biotechnology company specialising in the extraction of biomolecules of high therapeutic value from tissues of animal origin and it is continuously developing new compounds that may be able to be applied in science. It is a worldwide reference for the production of heparin (the most used anticoagulant) and chondroitin sulfate (a drug for osteoarthritis).

If you could be interested in this project, please do not hesitate to contact us.

CONTACT US

WE WILL BE PLEASED TO HELP

Therapeutic Innovations

E-mail address:
humanhealth@bioiberica.com
Telephone number:
+34 93 490 49 08
Fax:
+34 93 490 97 11